Aims and scope
Trials encompasses all aspects of the performance and findings of randomized controlled trials in health. We publish articles on general trial methodology and research into trial processes, as well as study protocols and statistical analysis plans for randomised controlled trials, commentaries and traditional results papers - regardless of outcome or significance of findings.
Our aim is to promote transparency in the reporting of randomised trials and build an evidence base that will help inform the design and reporting of future trials. Within this remit, we consider articles or study protocols assessing aspects of the design, conduct or reporting of trials, as well as assessment and evaluation of lessons learnt from past trials, including those that were prematurely ended. We advocate for the collective success for trials and the importance of linking publications together (the thread of evidence).
To facilitate complete and transparency reporting of research, Trials does not ask authors to adhere to strict word limits. We request that authors provide the detail required to make the research replicable. We ask that authors communicate not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide.
Trials aims to experiment with, and refine, innovative approaches to improving communication about randomized controlled trials. We are keen to move beyond publishing traditional trial results articles (although these are included), and we believe this journal represents an exciting opportunity to advance the science and reporting of trials.
All articles published by Trials are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Trials you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Trials therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
Trials is involved in a pilot study of new technology enabling the setting of article processing charges (APCs) at an article-type level within a journal instead of charging at a flat rate. APCs on this journal are as follows for the duration of the pilot:
|Article type||APC GBP*||APC EURO*||APC USD*|
*Plus VAT or local taxes where applicable
All articles published in Trials are included in:
- Current contents
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Trials operates an open peer-review system, where the reviewers' names are included on the peer review reports for authors. In addition, if the article is published, the named reviewer reports are published online alongside the article under a Creative Commons Attribution License 4.0. Previous versions of the manuscript and all author responses to the reviewers are available by contacting email@example.com.
The benefit of open peer review is that it increases transparency. The peer reviewers and Editors are fully accountable for the decisions made, bias is reduced as reviewer reports are named, published reports can serve an educational purpose in helping facilitate training and research into peer review, and reviewers can get credit for their work.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Trials should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Trials
Articles in Trials should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Trials [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Trials 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Trials
Trials's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Trials offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Trials gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Trials are included in article alerts and regular email updates. Some may be highlighted on Trials’s pages and on the BioMed Central homepage.
In addition, articles published in Trials may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Trials. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Trials you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
2017 Journal Metrics
139 days to first decision for reviewed manuscripts only
119 days to first decision for all manuscripts
193 days from submission to acceptance
28 days from acceptance to publication
6,102 Altmetric mentions